Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on June 17, 2009. The report details a Variation and Settlement Agreement entered into with Avecia Biologics Limited regarding the discharge of obligations under a prior Master Services Agreement related to biodefense vaccine development.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial items disclosed include:
- Deferred Consideration: $7 million payable to Avecia.
- Security Instrument: A $7 million letter of credit previously secured by restricted cash.
- Balance Sheet Classification: As of December 31, 2008, and March 31, 2009, the cash securing the letter of credit was classified as restricted cash (current assets), and the liability was classified as accrued expenses and other current liabilities.
Material Changes
The primary material change is the acceleration of the payment obligation for the Deferred Consideration. Originally payable upon the earlier of a $15 million financing or October 2, 2009, the Settlement Agreement requires payment by June 30, 2009. Upon payment, the $7 million letter of credit will be terminated.
Outlook, Risks, and Management Commentary
Management notes that the Settlement Agreement governs the discharge of liabilities under the Master Services Agreement as part of transferring the manufacturing process for a bulk rPA drug substance from Avecia to a US-based contract manufacturer. The full text of the agreement will be attached as an exhibit to the Form 10-Q for the period ended June 30, 2009.
Investor Verification Checklist
- Verify the actual payment of the $7 million Deferred Consideration by the June 30, 2009 deadline.
- Confirm the termination of the $7 million letter of credit following payment.
- Review the upcoming Form 10-Q for the quarter ended June 30, 2009, for the full text of the Settlement Agreement and updated balance sheet impacts.
- Note the discrepancy between the requested company name (Altimmune, Inc.) and the filing registrant (PharmAthene, Inc.).